Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

Be careful trusting TikTok for gout advice

Written by | 26 Dec 2025

A new paper in Rheumatology Advances in Practice, published by Oxford University Press, indicates that Tik Tok videos about gout are commonly misleading, inconsistent, or inaccurate. Gout is a painful… read more.

Amgen presents new data that show blood decreases for adults treated with Krystexxa (pegloticase)

Written by | 7 Nov 2023

Amgen announced new data for Krystexxa (pegloticase) showing a decrease in blood pressure during treatment of adults living with chronic gout refractory to oral urate-lowering treatment; uncontrolled gout,… read more.

A sharp increase in the price of the gout drug colchicine led to lower use and poorer disease control, UCLA research suggests

Written by | 11 May 2023

Due to a policy decision in 2010 by the U.S. Food and Drug Administration (FDA), the price of a prescription for the therapeutic gout drug colchicine increased nearly… read more.

Phase III MIRROR trial of Krystexxa meets primary endpoint in chronic gout – Horizon Therapeutics

Written by | 1 Nov 2021

Horizon Therapeutics announced topline results of the phase III MIRROR trial met the primary endpoint, showing a significant increase in efficacy using Krystexxa (pegloticase injection) with the immunomodulator… read more.

Gout drug shows preliminary efficacy with hospitalized COVID-19 patients

Written by | 18 Feb 2021

Article written by Bruce Sylvester Colchicine, a gout treatment, appears to reduce the need for oxygen therapy in COVID-19 patients, researchers reported on Feb. 4, 2021 in the… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.